The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...
Please provide your email address to receive an email when new articles are posted on . The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity ...
Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous administration of Tysabri rather than IV, citing shorter duration of delivery and ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
NEW YORK (Reuters Health) - Subcutaneous daratumumab could offer an effective and more convenient alternative to the intravenous formulation for patients with relapsed or refractory multiple myeloma, ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results